Wells Fargo’s Marker Therapeutics MRKR Stock Holding History

Wells Fargo’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$302	Sell	232 -10	-4%	-$16	﹤0.01%	6434
2025 Q4	$361	Hold	242	–	–	﹤0.01%	6357
2025 Q3	$216	Buy	242 +10	+4%	+$12	﹤0.01%	6341
2025 Q2	$355	Hold	232	–	–	﹤0.01%	6408
2025 Q1	$285	Hold	232	–	–	﹤0.01%	6309
2024 Q4	$722	Hold	232	–	–	﹤0.01%	6288
2024 Q3	$654	Hold	232	–	–	﹤0.01%	6154
2024 Q2	$1.26K	Sell	232 -52	-18%	-$221	﹤0.01%	6074
2024 Q1	$1.22K	Buy	284 +1	+0.4%	+$4	﹤0.01%	6110
2023 Q4	$1.56K	Buy	283 +3	+1%	+$10	﹤0.01%	6138
2023 Q3	$1.27K	Buy	280 +3	+1%	+$17	﹤0.01%	6160
2023 Q2	$859	Buy	277 +4	+1%	+$7	﹤0.01%	6353
2023 Q1	$194	Hold	273	–	–	﹤0.01%	6781
2022 Q4	$725	Buy	273 +1	+0.4%	+$3	﹤0.01%	6281
2022 Q3	$1K	Sell	272 -1	-0.4%	-$4	﹤0.01%	6399
2022 Q2	$1K	Buy	273 +4	+1%	+$13	﹤0.01%	6554
2022 Q1	$1K	Hold	269	–	–	﹤0.01%	6831
2021 Q4	$2K	Sell	269 -100	-27%	-$1.33K	﹤0.01%	6898
2021 Q3	$7K	Sell	369 -3	-0.8%	-$61	﹤0.01%	6303
2021 Q2	$10K	Sell	372 -706	-65%	-$18.6K	﹤0.01%	6144
2021 Q1	$23K	Sell	1,078 -4,113	-79%	-$94.1K	﹤0.01%	6110
2020 Q4	$75K	Sell	5,191 -3,477	-40%	-$54K	﹤0.01%	5459
2020 Q3	$130K	Sell	8,668 -394	-4%	-$7.19K	﹤0.01%	5156
2020 Q2	$188K	Buy	9,062 +6,222	+219%	+$136K	﹤0.01%	4946
2020 Q1	$54K	Sell	2,840 -314	-10%	-$8K	﹤0.01%	5310
2019 Q4	$91K	Sell	3,154 -1,705	-35%	-$62K	﹤0.01%	5341
2019 Q3	$248K	Buy	4,859 +1,716	+55%	+$101K	﹤0.01%	4833
2019 Q2	$249K	Buy	+3,143	New	+$187K	﹤0.01%	4845

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Wells Fargo's MRKR Position: Q1 2026 in Review

Wells Fargo reduced its Marker Therapeutics (MRKR) stake by 4.1% in Q1 2026, selling an estimated $16 and leaving 232 shares worth $302. The position accounts for ﹤0.01% of the portfolio, ranked #6434.

Wells Fargo first reported a position in MRKR in Q2 2019 and has held it in 28 quarters since. The position peaked at $249K in Q2 2019. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

Wells Fargo held 232 shares of Marker Therapeutics worth $302 as of Q1 2026.
Wells Fargo sold 10 Marker Therapeutics shares in Q1 2026, an estimated $16.
Marker Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6434 holding.
Wells Fargo first reported a position in Marker Therapeutics in Q2 2019 and has held it in 28 quarters since.
Wells Fargo's Marker Therapeutics position peaked at $249K in Q2 2019.
35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.